The therapeutic effects of targeted transcranial direct current stimulation on herpes zoster-associated pain: A randomized, single-blind, controlled trial.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500100949

Enrollment

Unknown

Registered

2025-04-17

Start date

2024-12-01

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression and anxiety in patients with herpes zoster-related pain

Interventions

Transcranial direct current stimulation one group:Transcranial direct current stimulation therapy was used, and the stimulation mode was anodic stimulation of the patients left dorsolateral prefrontal

Transcranial direct current stimulation two group:Transcranial direct current stimulation therapy instruments were used to stimulate the patients left dorsolateral prefrontal cortex with anodic stimul

control group:The stimulation mode of the control group was to use anodic stimulation to stimulate the patients left dorsolateral prefrontal cortex, cathodic stimulation to the right dorsolateral pref

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for herpes zoster-associated pain; (2) Age >= 18 years old; (3) NRS score >= 4 points (moderate to severe pain); (4) Hamilton Depression Rating Scale score > 7 points or Hamilton Anxiety Scale score > 7 points.

Exclusion criteria

Exclusion criteria: (1) Combined with intracranial organic lesions or head trauma; (2) Are taking naloxone and other drugs that interfere with the analgesic effect of transcranial direct current stimulation; (3) Those who have been previously diagnosed with severe mental illness; (4) Patients with abnormal function of important organs such as heart, liver, kidney, etc.; (5) Those with pacemakers, brain stimulation devices, intracranial metal implant devices, such as arterial clips, skull repairs, etc.; (6) Ventricular-abdominal shunt; (7) patients with epilepsy that is not well controlled; (8) Those who are unable to communicate normally and cannot complete the questionnaire assessment independently; (9) Patients with serious adverse reactions to conventional antiviral drugs, central analgesic drugs, and tricyclic antidepressants.

Design outcomes

Primary

Measure	Time frame
Pain;	—

Secondary

Measure	Time frame
Depression score;Anxiety score;pain;Sleep quality;	—

Countries

China

Contacts

Public ContactLiping Chen

Affiliated Hospital of Xuzhou Medical University

1132927346@qq.com+86 137 7587 0371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026